These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18056170)

  • 21. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer.
    Woo HH; Zhou Y; Yi X; David CL; Zheng W; Gilmore-Hebert M; Kluger HM; Ulukus EC; Baker T; Stoffer JB; Chambers SK
    Oncogene; 2009 Mar; 28(9):1176-86. PubMed ID: 19151756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The molecular pathology of hereditary breast cancer.
    Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
    Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
    Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
    J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma.
    Erkinheimo TL; Sivula A; Lassus H; Heinonen M; Furneaux H; Haglund C; Butzow R; Ristimäki A
    Gynecol Oncol; 2005 Oct; 99(1):14-9. PubMed ID: 16126263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma.
    Xu F; Zhang X; Lei Y; Liu X; Liu Z; Tong T; Wang W
    J Cell Biochem; 2010 Oct; 111(3):727-34. PubMed ID: 20626035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?
    Troudi W; Uhrhammer N; Ben Romdhane K; Sibille C; Mahfoudh W; Chouchane L; Ben Ayed F; Bignon YJ; Ben Ammar Elgaaied A
    Eur J Histochem; 2007; 51(3):219-26. PubMed ID: 17921118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histologic specimens.
    Rassi H; Houshmand M; Hashemi M; Majidzadeh K; Akbari MH; Panahi MS
    Tsitol Genet; 2008; 42(2):55-62. PubMed ID: 18630122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence.
    Ortega AD; Sala S; Espinosa E; González-Barón M; Cuezva JM
    Carcinogenesis; 2008 Nov; 29(11):2053-61. PubMed ID: 18687667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
    Kotsopoulos J; Librach CL; Lubinski J; Gronwald J; Kim-Sing C; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Randall S; Manoukian S; Pasini B; Tung N; Ainsworth PJ; Cummings S; Sun P; Narod SA;
    Cancer Causes Control; 2008 Dec; 19(10):1111-9. PubMed ID: 18509731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
    De Vecchi G; Verderio P; Pizzamiglio S; Manoukian S; Bernard L; Pensotti V; Volorio S; Ravagnani F; Radice P; Peterlongo P
    Cancer Detect Prev; 2008; 32(2):140-3. PubMed ID: 18640791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
    Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
    Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
    Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A
    Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.